RxDoctor Payments DataLook up a doctor →

Juan Otero, MD

Endocrinology, Diabetes & Metabolism · Caguas, PRNPI 1871590968

Payments from drug & device makers

$451,706in general payments, 2019–2025

Across 254 payments — averaging $1778.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly Export S.A. Puerto Rico Branch$417K
  • Eli Lilly$15K
  • Johnson & Johnson$15K
  • AstraZeneca$871
  • Sanofi-aventis U.S. LLC$845
  • Boehringer Ingelheim$604
  • plus $3K from 17 others
$334,568in research payments, 2019–2025

Across 19 payments — averaging $17,609 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly Export S.A. Puerto Rico Branch$279K
  • Eli Lilly$56K

What the payments were for

  • Consulting fees$3752%
  • Speaking & faculty fees$12,66058%
  • Travel & lodging$2,48811%
  • Food & beverage$6,06728%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$451,706 in reported general payments places this provider in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

See all endocrinology, diabetes & metabolism providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$4,454
Medicare patients
36
Services billed
57

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide165$174,175
FarxigaDapagliflozin Propanediol120$89,336
JanumetSitagliptin Phos/Metformin Hcl115$75,622
SynthroidLevothyroxine Sodium1,125$53,960
Janumet XrSitagliptin Phos/Metformin Hcl65$42,679
TradjentaLinagliptin66$38,548
JardianceEmpagliflozin43$37,477
JanuviaSitagliptin Phosphate45$35,630
Synjardy XrEmpagliflozin/Metformin Hcl47$34,504
Jentadueto XrLinagliptin/Metformin Hcl50$33,864
Soliqua 100-33Insulin Glargine/Lixisenatide35$32,908
Xigduo XrDapaglifloz Propaned/Metformin55$31,914
JentaduetoLinagliptin/Metformin Hcl38$24,089
HumalogInsulin Lispro117$21,480
OzempicSemaglutide21$20,426

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Humalog, Humalog Mix 75-25, Humulin 70-30, Humulin N$396$215,312398 claims
Boehringer IngelheimTradjenta, Jardiance, Synjardy Xr, Jentadueto Xr, Jentadueto$604$188,074270 claims
MerckJanumet, Janumet Xr, Januvia$124$153,930225 claims
AstraZenecaFarxiga$871$89,336120 claims
AbbVieSynthroid$123$53,9601,125 claims
Sanofi-aventis U.S. LLCSoliqua 100-33, Lantus$845$50,014168 claims
Novo NordiskOzempic, Rybelsus$535$32,08733 claims
Johnson & JohnsonInvokana$14,618$15,13918 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 143 endocrinology, diabetes & metabolism providers in Puerto Rico.

Other endocrinology, diabetes & metabolism in Caguas

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →